BriaCell Therapeutics, Zacks Small Cap Research and Colin Sprake from Make Your Mark on CEO Money


with Guests:

William Williams M.D.
President and CEO – BriaCell Therapeutics Corporation
http://briacell.com/

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams served as VP of Exploratory Development at Incyte Corporation from 2005 – 2016. There he facilitated entry of over 20 compounds into the clinic, including ruxolitinib (Jakafi), baricitinib, and epacadostat.

John Vandermosten
Senior Biotechnology Analyst – Zacks Small Cap Research
http://scr.zacks.com

John Vandermosten is currently a senior biotechnology research analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 15 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure.
In the past John has mentioned some of the leading cancer therapies that are making waves. There is one approach that is not so well known, but might be one of the most flexible platforms out there. It is called interference RNA.
What is interference RNA? In simplest terms, interference RNA silences genes and stops specific protein production. Most people are familiar with DNA, which is the genetic code that resides in our cells. RNA is responsible for coding DNA information so cells can make proteins. A lot of disease, including cancer can be traced back to the proteins that cells manufacture. Interference RNA disrupts this messaging. It is a way that the body and science can turn off genes and stop specific proteins from being made; proteins that have an impact on diseases like macular degeneration, hepatitis, HIV, cancer and others.

Colin Sprake
Author, Speaker – Make Your Mark

Homepage – New Site

4 Time Best-selling Author and mentor to over 47,000 entrepreneurs!
Colin has built several different million-dollar businesses within 6 months. He has over 30 years of business experience having come from the mining industry to building his own multi-million-dollar businesses from the ground up.
Colin is the master trainer at Make Your Mark Training and Consulting and is devoted to people achieving huge success in their businesses. His purpose is to assist business owners to dramatically improve the amount of businesses that succeed. After all, failing businesses affect us all in negative ways.

Be the first to comment on "BriaCell Therapeutics, Zacks Small Cap Research and Colin Sprake from Make Your Mark on CEO Money"

Leave a comment

Your email address will not be published.


*